Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.

@article{Laverdire2002PolymorphismGI,
  title={Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.},
  author={Caroline Laverdi{\`e}re and Sonia Chiasson and Irina Costea and Albert Moghrabi and Maja Krajinovic},
  journal={Blood},
  year={2002},
  volume={100 10},
  pages={3832-4}
}
Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of childhood acute lymphoblastic leukemia (ALL). Resistance to this drug may arise by, among other factors, altered cellular uptake that may hamper the efficacy of the treatment. Recently, a G(80)A polymorphism has been described in the reduced folate carrier gene (RFC1), which encodes the major MTX transporter. Here, we assessed the association between the genetic polymorphisms G(80)A and both MTX plasma… CONTINUE READING